Free Trial

Nuveen Asset Management LLC Sells 37,994 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

Arcus Biosciences logo with Medical background

Nuveen Asset Management LLC reduced its position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 22.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 131,859 shares of the company's stock after selling 37,994 shares during the period. Nuveen Asset Management LLC owned about 0.14% of Arcus Biosciences worth $1,963,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the company. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Arcus Biosciences by 140.6% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 76,646 shares of the company's stock valued at $1,141,000 after buying an additional 44,784 shares during the last quarter. Millennium Management LLC raised its stake in Arcus Biosciences by 277.1% during the 4th quarter. Millennium Management LLC now owns 924,369 shares of the company's stock valued at $13,764,000 after buying an additional 679,267 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Arcus Biosciences by 2.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company's stock valued at $506,000 after buying an additional 833 shares during the last quarter. Lazard Asset Management LLC raised its stake in Arcus Biosciences by 3,321.3% during the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company's stock valued at $93,000 after buying an additional 6,078 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Arcus Biosciences during the 4th quarter valued at $6,928,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Wells Fargo & Company decreased their target price on shares of Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Barclays decreased their target price on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a research note on Wednesday, April 23rd. The Goldman Sachs Group decreased their target price on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Wedbush restated an "outperform" rating and issued a $33.00 price objective on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Finally, Morgan Stanley reduced their price objective on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $24.13.

Get Our Latest Stock Analysis on Arcus Biosciences

Arcus Biosciences Price Performance

Arcus Biosciences stock traded up $0.02 during mid-day trading on Thursday, hitting $9.62. The stock had a trading volume of 638,981 shares, compared to its average volume of 864,337. The firm has a market capitalization of $1.02 billion, a P/E ratio of -3.05 and a beta of 0.88. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm's 50 day moving average is $8.33 and its 200 day moving average is $11.51. Arcus Biosciences, Inc. has a one year low of $6.50 and a one year high of $18.98.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.12). The firm had revenue of $28.00 million during the quarter, compared to the consensus estimate of $38.61 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company's quarterly revenue was down 80.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.05) EPS. On average, sell-side analysts forecast that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

About Arcus Biosciences

(Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Recommended Stories

Institutional Ownership by Quarter for Arcus Biosciences (NYSE:RCUS)

Should You Invest $1,000 in Arcus Biosciences Right Now?

Before you consider Arcus Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.

While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines